Clavanin a improves outcome of complications from different bacterial infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1620-1626

  Silva, Osmar N ^a   Fensterseifer, Isabel C M ^b,c   Rodrigues, Elaine A ^c   Holanda, Hortência H S ^c   Novaes, Natasha R F ^c   Cunha, Junia P A ^c   Rezende, Taia M B ^c   Magalhães, Kelly G ^b   Moreno, Susana E ^c   Jerônimo, Márcio S ^b   Bocca, Anamélia L ^b   Franco, Octavio L ^a,b,c,d  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^d UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CLAVANIN A; GENTAMICIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; PEPTIDE; PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; ESCHERICHIA COLI; EXPERIMENTAL SURGICAL WOUND; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SKIN CELL; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD PROTEINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICE; MICE, INBRED C57BL; PEPTIDES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84923240008     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03732-14     Document Type: Article

References (41)

1. Murray CJ, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, Salomon JA, Michaud CM, Walker N, Vos T. 2007. Global burden of disease 2005: call for collaborators. Lancet 370:109-110. http://dx.doi.org/10.1016/S0140-6736(07)61064-2.
2. O'Dell ML. 1998. Skin and wound infections: an overview. Am Fam Physician 57:2424-2432.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310. http://dx.doi.org/10.1097/00003246-200107000-00002.
4. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. 2003. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 167:695-701. http://dx.doi.org/10.1164/rccm.200207-682OC.
5. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. 2006. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344-353. http://dx.doi.org/10.1097/01.CCM.0000194725.48928.3A.
6. Rittirsch D, Flierl MA, Ward PA. 2008. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776-787. http://dx.doi.org/10.1038/nri2402.
7. Namas R, Zamora R, An G, Doyle J, Dick TE, Jacono FJ, Androulakis IP, Nieman GF, Chang S, Billiar TR, Kellum JA, Angus DC, Vodovotz Y. 2012. Sepsis: something old, something new, and a systems view. J Crit Care 27:314.e1-11. http://dx.doi.org/10.1016/j.jcrc.2011.05.025.
8. Marti-Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF. 2012. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 12:CD004388. http://dx.doi.org/10.1002/14651858.CD004388.pub6.
9. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N. 2000. E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283:1723-1730. http://dx.doi.org/10.1001/jama.283.13.1723.
10. Silva ON, Mulder KC, Barbosa AE, Otero-Gonzalez AJ, Lopez-Abarrategui C, Rezende TM, Dias SC, Franco OL. 2011. Exploring the pharmacological potential of promiscuous host-defense peptides: from natural screenings to biotechnological applications. Front Microbiol 2:232. http://dx.doi.org/10.3389/fmicb.2011.00232.
11. Levi M, Ten Cate H. 1999. Disseminated intravascular coagulation. N Engl J Med 341:586-592. http://dx.doi.org/10.1056/NEJM199908193410807.
12. Lee IH, Zhao C, Cho Y, Harwig SS, Cooper EL, Lehrer RI. 1997. Clavanins, alpha-helical antimicrobial peptides from tunicate hemocytes. FEBS Lett 400: 158-162. http://dx.doi.org/10.1016/S0014-5793(96)01374-9.
13. van Kan EJ, Demel RA, van der Bent A, de Kruijff B. 2003. The role of the abundant phenylalanines in the mode of action of the antimicrobial peptide clavanin. Biochim Biophys Acta 1615:84-92. http://dx.doi.org/10.1016/S0005-2736(03)00233-5.
14. Lee IH, Cho Y, Lehrer RI. 1997. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun 65:2898-2903.
15. Maggiora LL, Smith CW, Zhang ZY. 1992. A general method for the preparation of internally quenched fluorogenic protease substrates using solid-phase peptide synthesis. J Med Chem 35:3727-3730. http://dx.doi.org/10.1021/jm00099a001.
16. Wiegand I, Hilpert K, Hancock RE. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3:163-175. http://dx.doi.org/10.1038/nprot.2007.521.
17. Steinstraesser L, Hirsch T, Schulte M, Kueckelhaus M, Jacobsen F, Mersch EA, Stricker I, Afacan N, Jenssen H, Hancock RE, Kindrachuk J. 2012. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS One 7:e39373. http://dx.doi.org/10.1371/journal.pone.0039373.
18. Silva ON, Porto WF, Migliolo L, Mandal SM, Gomes DG, Holanda HHS, Silva RSP, Dias SCD, Costa MP, Costa CR, Silva MRS, Rezende TMB, Franco OL. 2012. Cn-AMP1: a new promiscuous peptide with potential for microbial infections treatment. Biopolymers 98:322-331. http://dx.doi.org/10.1002/bip.22071.
19. Zhang ZG, Bothe I, Hirche F, Zweers M, Gullberg D, Pfitzer G, Krieg T, Eckes B, Aumailley M. 2006. Interactions of primary fibroblasts and keratinocytes with extracellular matrix proteins: contribution of alpha2beta1 integrin. J Cell Sci 119:1886-1895. http://dx.doi.org/10.1242/jcs.02921.
20. Lopez-Abarrategui C, Alba A, Silva ON, Reyes-Acosta O, Vasconcelos IM, Oliveira JT, Migliolo L, Costa MP, Costa CR, Silva MR, Garay HE, Dias SC, Franco OL, Otero-Gonzalez AJ. 2012. Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus. Biochimie 94:968-974. http://dx.doi.org/10.1016/j.biochi.2011.12.016.
21. Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A. 2002. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother 46:689-694. http://dx.doi.org/10.1128/AAC.46.3.689-694.2002.
22. McRipley RJ, Whitney RR. 1976. Characterization and quantitation of experimental surgical-wound infections used to evaluate topical antibacterial agents. Antimicrob Agents Chem 10:38-44. http://dx.doi.org/10.1128/AAC.10.1.38.
23. Zaleski KJ, Kolodka T, Cywes-Bentley C, McLoughlin RM, Delaney ML, Charlton BT, Johnson W, Tzianabos AO. 2006. Hyaluronic acid binding peptides prevent experimental staphylococcal wound infection. Antimicrob Agents Chem 50:3856-3860. http://dx.doi.org/10.1128/AAC.00082-06.
24. Jacobsen F, Baraniskin A, Mertens J, Mittler D, Mohammadi-Tabrisi A, Schubert S, Soltau M, Lehnhardt M, Behnke B, Gatermann S, Steinau HU, Steinstraesser L. 2005. Activity of histone H1.2 in infected burn wounds. J Antimicrob Chemother 55:735-741. http://dx.doi.org/10.1093/jac/dki067.
25. Lima TB, Silva ON, Silva LP, Rocha TL, Grossi-de-Sa MF, Franco OL, Leonardecz E. 2011. In vivo effects of cagaita (Eugenia dysenterica, DC.) leaf extracts on diarrhea treatment. Evid Based Comp Altern Med 2011: 309390. http://dx.doi.org/10.1155/2011/309390.
26. Qiu XQ, Wang H, Lu XF, Zhang J, Li SF, Cheng G, Wan L, Yang L, Zuo JY, Zhou YQ, Wang HY, Cheng X, Zhang SH, Ou ZR, Zhong ZC, Cheng JQ, Li YP, Wu GY. 2003. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat Biotechnol 21:1480-1485. http://dx.doi.org/10.1038/nbt913.
27. van Kan EJ, Ganchev DN, Snel MM, Chupin V, van der Bent A, de Kruijff B. 2003. The peptide antibiotic clavanin A interacts strongly and specifically with lipid bilayers. Biochemistry 42:11366-11372. http://dx.doi.org/10.1021/bi0349017.
28. van Kan EJ, van der Bent A, Demel RA, de Kruijff B. 2001. Membrane activity of the peptide antibiotic clavanin and the importance of its glycine residues. Biochemistry 40:6398-6405. http://dx.doi.org/10.1021/bi0028136.
29. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273:3718-3724. http://dx.doi.org/10.1074/jbc.273.6.3718.
30. Carriel-Gomes MC, Kratz JM, Barracco MA, Bachere E, Barardi CR, Simoes CM. 2007. In vitro antiviral activity of antimicrobial peptides against herpes simplex virus 1, adenovirus, and rotavirus. Mem Inst Oswaldo Cruz 102:469-472. http://dx.doi.org/10.1590/S0074-02762007005000028.
31. Ahmad I, Perkins WR, Lupan DM, Selsted ME, Janoff AS. 1995. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1237:109-114. http://dx.doi.org/10.1016/0005-2736(95)00087-J.
32. McGwire BS, Olson CL, Tack BF, Engman DM. 2003. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis 188:146-152. http://dx.doi.org/10.1086/375747.
33. Lehrer RI, Lichtenstein AK, Ganz T. 1993. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 11:105-128. http://dx.doi.org/10.1146/annurev.iy.11.040193.000541.
34. Ohsaki Y, Gazdar AF, Chen HC, Johnson BE. 1992. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 52:3534-3538.
35. Rinaldi AC, Mangoni ML, Rufo A, Luzi C, Barra D, Zhao H, Kinnunen PK, Bozzi A, Di Giulio A, Simmaco M. 2002. Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. Biochem J 368:91-100. http://dx.doi.org/10.1042/BJ20020806.
36. Malmsten M, Kasetty G, Pasupuleti M, Alenfall J, Schmidtchen A. 2011. Highly selective end-tagged antimicrobial peptides derived from PRELP. PLoS One 6:e16400. http://dx.doi.org/10.1371/journal.pone.0016400.
37. Lee YS, Shin YP, Shin SH, Park S, Kim MH, Lee IH. 2011. Therapeutic efficacy of halocidin-derived peptide HG1 in a mouse model of surgical wound infection with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:1296-1299. http://dx.doi.org/10.1128/AAC.00948-10.
38. Chalekson CP, Neumeister MW, Jaynes J. 2003. Treatment of infected wounds with the antimicrobial peptide D2A21. J Trauma 54:770-774. http://dx.doi.org/10.1097/01.TA.0000047047.79701.6D.
39. Lipsky BA, Holroyd KJ, Zasloff M. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 47:1537-1545. http://dx.doi.org/10.1086/593185.
40. Van Amersfoort ES, Van Berkel TJ, Kuiper J. 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16:379-414. http://dx.doi.org/10.1128/CMR.16.3.379-414.2003.
41. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Silvestri C, Mocchegiani F, Licci A, Skerlavaj B, Rocchi M, Saba V, Zanetti M, Scalise G. 2006. LL-37 protects rats against lethal sepsis caused by Gramnegative bacteria. Antimicrob Agents Chemother 50:1672-1679. http://dx.doi.org/10.1128/AAC.50.5.1672-1679.2006.